January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Final Overall Survival in the Phase III FALCON Trial
Jan 22, 2025, 11:03

Final Overall Survival in the Phase III FALCON Trial

Kristina Jankovic, Medical Oncology Resident at the University Clinical Center Niš, shared an article by John F.R. Robertso on X:

“Final OS analysis from FALCON:

  • No significant difference between fulvestrant (44.8 months) and anastrozole (42.7 months) in ET-naive HR+ ABC.
  • 15% risk of death with fulvestrant in nonvisceral disease (65.2 vs. 47.8 months).”

Fulvestrant Versus Anastrozole in Endocrine Therapy–Naïve Women With Hormone Receptor–Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial.

Authors: John F.R. Robertso, et al.

Final Overall Survival in the Phase III FALCON Trial